Premium
Prognostic value of the immunoexpression of chemoresistance‐related proteins in cerebral glioblastomas: An analysis of 168 cases
Author(s) -
Korshunov Andrey,
Golanov Andrey,
Sycheva Regina,
Pronin Igor,
Fadeeva Luidmila
Publication year - 1999
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1046/j.1440-1789.1999.00228.x
Subject(s) - immunohistochemistry , medicine , glioma , glioblastoma , antigen , chemotherapy , pathology , proportional hazards model , multivariate analysis , cancer , brain tumor , antibody , oncology , cancer research , immunology
A variety of chemotherapy protocols have been in‐troduced for the treatment of glioblastoma, although overall these have not contributed to patient outcome. Data on the prognostic value of immunoexpression of chemoresistance‐related proteins in malignant gliomas are very limited. One hundred and sixty‐eight patients with cerebral glioblastomas who received combined treatment were studied retrospectively. Tumor specimens were immunohistochemically examined with antibodies to glutathione S ‐transferase pi (GST pi), P‐glycoprotein (P‐GP) and metallothioneins (MT). The results demonstrated that survival time was found to be significantly shorter for glioblastomas containing = or > 20% of GST pi‐immunostained cells and for tumors with P‐GP positivity in neoplastic cells. In contrast, the survival time was found to be significantly longer in patients with neoplasms containing = or > 50% of MT‐positive cells. Multivariate Cox regression analysis with application of clinical and immunohistochemical factors revealed independent prog‐nostic significance for all of the above‐mentioned varia‐tions of protein expression. The findings suggest that variables of expression of the chemoresistance‐related antigens are predictors for outcome in glioblastoma and that immunohistochemical analysis may provide useful information for the determination of optimal anti‐cancer strategies in each case.